Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib‐dexamethasone versus physician's choice
Sign Up to like & getrecommendations! Published in 2023 at "American Journal of Hematology"
DOI: 10.1002/ajh.26866
Abstract: Patient‐reported outcomes in AL amyloidosis have not been well‐studied. We analyzed health‐related quality of life (HRQOL) and AL amyloidosis symptoms data from the phase 3 TOURMALINE‐AL1 trial (NCT01659658) (ixazomib‐dexamethasone, n = 85; physician's choice of… read more here.
Keywords: ixazomib dexamethasone; physician choice; patients relapsed; quality life ... See more keywords
Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): Efficacy in patients with visceral metastases.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.1052
Abstract: 1052Background: The OlympiAD study showed a significant progression-free survival (PFS) benefit for olaparib over chemotherapy treatment of physician’s choice (TPC) in patients with HER2-negative m... read more here.
Keywords: her2 negative; treatment physician; physician choice; chemotherapy treatment ... See more keywords
Impact of olaparib vs physician’s choice of new hormonal agent (pcNHA) on burden of pain in metastatic castration-resistant prostate cancer (mCRPC): PROfound.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.5538
Abstract: 5538Background: In the Phase III PROfound study (NCT02987543) olaparib significantly improved radiographic progression-free survival (primary endpoint) vs pcNHA (enzalutamide or abiraterone) in pat... read more here.
Keywords: choice new; physician choice; impact olaparib; olaparib physician ... See more keywords
Ixazomib-dexamethasone (Ixa-Dex) vs physician’s choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.8546
Abstract: 8546Background: The PI bortezomib is commonly used in first-line therapy of AL, but new therapies are needed that are tolerable in the context of multi-organ dysfunction and that, in RRAL, offer im... read more here.
Keywords: dexamethasone ixa; physician choice; dex physician; ixazomib dexamethasone ... See more keywords
First-line Gemcitabine Versus Treatment of Physician’s Choice for Metastatic Breast Cancer: A Prospective Cohort Study
Sign Up to like & getrecommendations! Published in 2021 at "AntiCancer Research"
DOI: 10.21873/anticanres.14930
Abstract: Background/Aim: This study aimed to investigate the efficacy of first-line gemcitabine monotherapy for metastatic breast cancer (MBC) and its effect on health-related quality of life (HRQoL) compared with treatment of physician’s choice (TPC). Patients and… read more here.
Keywords: physician choice; line gemcitabine; first line; treatment ... See more keywords